Since then, several recent and ongoing trials, including PENELOPE-B, have sought to demonstrate its efficacy also in high-risk ER+, HER2-, early breast cancer patients with residual disease after neoadjuvant chemotherapy (NACT) (14–17). This evidence concerns the gene ESR1 and breast cancer.